U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis [Internet]. Geneva: World Health Organization; 2018.

Cover of WHO treatment guidelines for isoniazid-resistant tuberculosis

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis [Internet].

Show details

References

1.
Global tuberculosis report 2017 [WHO/HTM/TB/2017.23] Available from: http://apps​.who.int/iris​/bitstream/10665​/259366/l/9789241565516-eng.pdf?ua=1 World Health Organization: Geneva. 2017.
2.
WHO handbook for guideline development – 2nd ed. Available from: http://apps​.who.int/iris​/bitstream/10665​/145714/1/9789241548960eng.pdf. World Health Organization: Geneva. 2014.
3.
Schünemann H, Brozek J, Gordon Guyatt G, Andrew Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach [Internet], 2013 [Updated October 2013] Available from: https://gdt​.gradepro​.org/app/handbook/handbook.html. 2013.
4.
WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision [WHO/HTM/TB/2016.04], Available from: http://apps​.who.int/iris​/bitstream/10665​/250125/1/9789241549639-eng.pdf. World Health Organization: Geneva. 2016. [PubMed: 27748093]
5.
Guidelines for the programmatic management of drug-resistant tuberculosis [WHO/HTM/TB/2006.361]. Available from: http://apps​.who.int/iris​/bitstream/10665​/246249/2/9789241546959-eng.pdf. World Health Organization: Geneva. 2006.
6.
Guidelines for the programmatic management of drug-resistant tuberculosis - Emergency update [WHO/HTM/TB/2008.402]. Available from: http://apps​.who.int/iris​/bitstream/10665​/43965/1/9789241547581eng.pdf. World Health Organization: Geneva. 2008.
7.
Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis [WHO/HTM/TB/2014.11]. Available from: http://apps​.who.int/iris​/bitstream/10665​/130918/1/9789241548809eng.pdf. World Health Organization: Geneva. 2014. [PubMed: 25320836]
8.
Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children [WHO/HTM/TB/2013.16]. Available from: http://apps​.who.int/iris​/bitstream/1Q665​/112472/1/9789241506335eng.pdf?ua=l. World Health Organization: Geneva. 2013. [PubMed: 25473701]
9.
The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin [WHO/HTM/TB/2016.12]. Available from: http://apps​.who.int/iris​/bitstream/10665​/250586/1/9789241511261-eng.pdf?ua=1. World Health Organization: Geneva. 2016.
10.
Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero J. Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2016;20(8):1099-1104. [PMC free article: PMC5310937] [PubMed: 27393546]
11.
Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2017;17(2):223-234. [PubMed: 27865891]
12.
Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, Venkatesan P et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030. [PMC free article: PMC3700922] [PubMed: 23843980]
13.
Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. New England Journal of Medicine. 2014;371(17):1588-1598. [PubMed: 25337748]
14.
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. New England Journal of Medicine. 2014;371(17): 1577-1587. [PMC free article: PMC4277680] [PubMed: 25196020]
15.
Fox GJ, Benedetti A, Mitnick CD, Pai M, Menzies D, Collaborative Group for Meta-Analysis of Individual Patient Data in M-T. Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS One. 2016;11(3):e0151724 (https://www​.ncbi.nlm​.nih.gov/pubmed/27022741, accessed. [PMC free article: PMC4811416] [PubMed: 27022741]
16.
The Cochrane collaboration. Cochrane handbook for systematic reviews of interventions Version 5.1.0. [updated March 2011]. Available from: http://handbook-5-1​.cochrane.org/. John Wiley & Sons. 2011.
17.
Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A et al. Rating quality of evidence and strength of recommendations: Going from evidence to recommendations. BMJ: British Medical Journal. 2008;336(7652):1049. [PMC free article: PMC2376019] [PubMed: 18467413]
18.
Tugwell P, Knottnerus JA. Advantages of individual patient data analysis in systematic reviews. Journal of clinical epidemiology. 2010;63(3):233-234. [PubMed: 20152706]
19.
Stewart LA, Tierney JF, Clarke M. Reviews of individual patient data. In: Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series 2008 Sep 22. John Wiley & Sons, Ltd, Chichester, UK, John Wiley & Sons, Ltd, Chichester, UK. 2008.
20.
Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. The Lancet Infectious Diseases. 2016;16(10):1185-1192. [PMC free article: PMC5030278] [PubMed: 27397590]
21.
The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance [WHO/HTM/TB/2016.07]. Available from: http://apps​.who.int/iris​/bitstream/10665​/246131/1/9789241510561-eng.pdf?ua=1. World Health Organization: Geneva. 2016.
22.
Ramachandran G, Kumar AH, Srinivasan R, Geetharani A, Sugirda P, Nandhakumar B et al. Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. The Indian journal of medical research. 2012;136(6):979. [PMC free article: PMC3612327] [PubMed: 23391793]
23.
Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32(2):101-119 (https://www​.ncbi.nlm​.nih.gov/pubmed/9068926, accessed. [PubMed: 9068926]
24.
University of Liverpool. HIV drug interaction checker [Updated December 2017]. Available from: https://www​.hiv-druginteractions​.org/checker.
25.
Lempens P, Meehan CJ, Vandelannoote K, Fissette K, de Rijk P, Van Deun A et al. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Scientific Reports. 2018;8(1):3246. [PMC free article: PMC5818527] [PubMed: 29459669]
26.
Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update [WHO/HTM/TB/2017.05]. Available from: http://apps​.who.int/iris​/bitstream/10665​/255052/1/9789241550000-eng.pdf?ua=1. World Health Organization: Geneva. 2017.
27.
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A et al. Official American Thoracic Society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clinical Infectious Diseases. 2016;63(7):e147-e195. [PMC free article: PMC6590850] [PubMed: 27516382]
28.
Global Drug Facility (GDF) catalogueProducts List. Available from: http://www​.stoptb.org​/gdf/drugsupply/drugs_available.asp. Stop TB Partnership: Geneva.
29.
Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014) [WHO/HTM/TB/2013.2]. Available from: http://apps​.who.int/iris​/bitstream/10665​/79199/1/9789241505345_eng.pdf. World Health Organization: Geneva. 2013.
30.
Guidance for national tuberculosis programmes on the management of tuberculosis in children [WHO/HTM/TB/2014.03]. Available from: http://apps​.who.int/iris​/bitstream/10665​/112360/1/9789241548748_eng.pdf?ua=1. Geneva: World Health Organization. 2014. [PubMed: 24999516]
31.
Blumberg H, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American journal of respiratory and critical care medicine. 2003;167(4):603. [PubMed: 12588714]
32.
Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clinical Infectious Diseases. 2012;55(8):1154-1163. [PubMed: 22820541]
33.
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach, 2nd ed. Available from: http://apps​.who.int/iris​/bitstream/10665​/208825/1/9789241549684_eng.pdf?ua=1. World Health Organization: Geneva. 2016. [PubMed: 27466667]
34.
Escalante P, Graviss EA, Griffith DE, Musser JM, Awe RJ. Treatment of isoniazid-resistant tuberculosis in southeastern Texas. CHEST Journal. 2001;119(6):1730-1736. [PubMed: 11399698]
35.
Nolan C, Goldberg S. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. The International Journal of Tuberculosis and Lung Disease. 2002;6(11):952-958. [PubMed: 12475140]
36.
Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Lim SY et al. Treatment of isoniazid-resistant pulmonary tuberculosis. BMC infectious diseases. 2008;8(1):6. [PMC free article: PMC2245946] [PubMed: 18211720]
37.
Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. Journal of Antimicrobial Chemotherapy. 2011;66(7):1431-1446. [PMC free article: PMC3112029] [PubMed: 21586591]
38.
Centers for Disease Control and Prevention (Atlanta). Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. MMWR. Morbidity and mortality weekly report. 2001;50(34):733. [PubMed: 11787580]
39.
Voogt G, Schoeman H. Ototoxicity of aminoglycoside drugs in tuberculosis treatment. The South African journal of communication disorders= Die Suid-Afrikaanse tydskrif vir Kommunikasieafwykings. 1996;43:3-6. [PubMed: 9265840]
40.
Gülbay BE, Gürkan ÖU, Yıldız ÖA, Önen ZP, Erkekol FÖ, BaÇÇıoğlu A et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respiratory medicine. 2006;100(10):1834-1842. [PubMed: 16517138]
41.
Bloss E, Kukša L, Holtz T, Riekstina V, Skripčonoka V, Kammerer S et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. The International Journal of Tuberculosis and Lung Disease. 2010;14(3):275-281. [PubMed: 20132617]
42.
Oxlade O, Falzon D, Menzies D. The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis. European Respiratory Journal. 2012;39(3):626-634. [PubMed: 21828030]
43.
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS medicine. 2012;9(8):e1001300. [PMC free article: PMC3429397] [PubMed: 22952439]
44.
Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis [WHO/HTM/TB/2017.13]. Available from: http://apps​.who.int/iris​/bitstream/10665​/259180/1/9789241512572-eng.pdf. World Health Organization: Geneva. 2017.
© World Health Organization 2018.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third-party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “The translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Bookshelf ID: NBK531415

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...